Novozymes A/S
NVZMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.10 | -1.87 | -1.36 | -0.60 |
| FCF Yield | 1.55% | 0.11% | 0.03% | 0.16% |
| EV / EBITDA | 80.65 | 80.12 | 60.72 | 65.99 |
| Quality | ||||
| ROIC | 1.02% | 7.23% | 10.52% | 7.02% |
| Gross Margin | 51.08% | 53.46% | 55.15% | 61.26% |
| Cash Conversion Ratio | 3.38 | 2.34 | 0.57 | 2.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.96% | 19.90% | 19.35% | 17.66% |
| Free Cash Flow Growth | 82.72% | 364.65% | -81.69% | -74.01% |
| Safety | ||||
| Net Debt / EBITDA | 8.50 | 1.13 | 0.47 | 0.55 |
| Interest Coverage | 13.05 | 91.47 | 102.68 | 36.89 |
| Efficiency | ||||
| Inventory Turnover | 0.70 | 4.42 | 4.94 | 4.01 |
| Cash Conversion Cycle | 153.16 | 22.85 | 20.12 | 18.96 |